arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Amphastar Pharmaceuticals, Inc.

AMPH
$27.66 ▼ -0.38 (-1.34%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
75
Health
Good
Neutral
auto_awesome

Analytical Summary

Amphastar Pharmaceuticals, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $1.2B
Dividend Yield —
Revenue Growth 5.4% ↗
Op. Margin 21.6% ↗
ROIC None
FCF / Share $0.98 ↗
Trailing P/E 40.1x
Price / Book —
FCF Yield 3.5%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$183.90M
↑ +5.4% —
Net Income Profit after all expenses
$6.42M
↓ -74.6% —
Operating Margin Operating profit as % of sales
21.6%
↑ +171.3% 74th
FCF / Share Free cash flow per share
$0.98
↑ +15.8% —
Long-Term Debt Long-term obligations
$619.71M
↓ -5.1% —

Health Breakdown

Profitability ↑
74
Financial Health ↓
76
Cash Quality ↑
74

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 15 years · 56 quarters